Patient characteristics of the data sets prior to matching
. | SHDT . | CT . |
|---|---|---|
| n | 66 | 291 |
| Female sex (%) | 16 (24) | 116 (40) |
| Age at study entry, y (range) | 51 (29-64) | 63 (30-87) |
| Binet stage at study entry (%) | ||
| A | 19 (29) | 155 (53) |
| B | 30 (45) | 89 (31) |
| C | 17 (26) | 46 (16) |
| Not available | 0 | 1 (0) |
| Lymphocyte count higher than 50 × 109/L (%) | 36 (55) | 87 (30) |
| VH homology less than 98% (%) | 22 (33) | 133 (46) |
| Deaths (%) | 8 (12) | 104 (36) |
| Median survival from diagnosis, mos | —* | 105 |
| Median follow-up, mos | 65 (11-185) | 68 (1-186) |
. | SHDT . | CT . |
|---|---|---|
| n | 66 | 291 |
| Female sex (%) | 16 (24) | 116 (40) |
| Age at study entry, y (range) | 51 (29-64) | 63 (30-87) |
| Binet stage at study entry (%) | ||
| A | 19 (29) | 155 (53) |
| B | 30 (45) | 89 (31) |
| C | 17 (26) | 46 (16) |
| Not available | 0 | 1 (0) |
| Lymphocyte count higher than 50 × 109/L (%) | 36 (55) | 87 (30) |
| VH homology less than 98% (%) | 22 (33) | 133 (46) |
| Deaths (%) | 8 (12) | 104 (36) |
| Median survival from diagnosis, mos | —* | 105 |
| Median follow-up, mos | 65 (11-185) | 68 (1-186) |
SHDT indicates sequential high-dose therapy including autologous stem cell transplantation; CT, conventional chemotherapy; —, not reached.
Median values and ranges are given for age at study entry.
Last observed death at 139 months (estimated survival probability: 0.61).